Levobunolol
| Evidence Level: N/A | Predicted Indications: 0 |
Table of Contents
- Levobunolol
Levobunolol: Known uses and market status in India
Summary
The TxGNN deep-learning model produced candidates for Levobunolol, but every candidate that can be traced to a source is already a known use. There is therefore currently no new predicted indication for this drug. The known uses are listed below by how they are supported.
Quick overview
| Item | Content |
|---|---|
| New predicted indications | None (all traceable model candidates are known uses) |
| Known uses among model candidates | 2 |
| Evidence level | Not applicable |
| India Market Status | Listed in a compiled Indian medicine price dataset (2 of 2) – CDSCO approval status is not included in this data |
| Number of Listed Products | 2 (valid: 2) |
Known uses among the model’s candidates
Approved (supported by a licence or label)
| Indication | Source |
|---|---|
| none | none |
Related to an approved indication (same disease category)
| Indication | Approved category |
|---|---|
| none | none |
Relations recorded in the knowledge graph (no approval found)
| Indication |
|---|
| glaucoma 1, open angle |
| open angle glaucoma |
India Market Information
| Licence | Product | Dosage form | Status |
|---|---|---|---|
| 31567 | Biozine 15mg Tablet | strip of 10 tablets | Valid |
| 27221 | Betagan 0.5% Liquifilm | packet of 5 ml Ophthalmic Solution | Valid |
Safety Considerations
- Contraindication-related diseases (from the knowledge graph, not label text): asthma (including intrinsic and allergic asthma), diabetes mellitus, diabetic ketoacidosis, myasthenia gravis and related neuromuscular junction disease, atrioventricular block, pulmonary emphysema, and anaphylaxis. Systemic beta-blocker precautions such as bradycardia and decompensated heart failure should also be considered.
- Drug Interactions: 24 interactions were recorded, none with a graded severity. Examples include omeprazole, pantoprazole, lansoprazole, warfarin, clopidogrel, prednisone, ibuprofen and tacrolimus. Interactions with oral beta-blockers and calcium channel blockers are of particular concern.
Please refer to the package insert for label warnings, as these were not available for this report.
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.